



PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/603,891	
			Filing Date	June 24, 2003	
			First Named Inventor	Kenneth F. Buechler	
			Art Unit	1641	
			Examiner Name	Unsu Jung	
Sheet	1	Of	10	Attorney Docket Number	36671-745.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2003/0022235 A1	01/30/2003	Dahlen et al.	
	2.	US 2003/0109420 A1	06/12/2003	Valkirs et al.	
	3.	US 2003/0119064 A1	06/26/2003	Valkirs et al.	
	4.	US 2003/0176814 A1	09/18/2003	Li	
	5.	US 2003/0199000 A1	10/23/2003	Valkirs et al.	
	6.	US 2003/0219734 A1	11/27/2003	Buechler	
	7.	US 2004/0121343 A1	06/24/2004	Buechler et al.	
	8.	US 2004/0121350 A1	06/24/2004	Anderberg et al.	
	9.	US 2004/0126767 A1	07/01/2004	Anderberg et al.	
	10.	US 2004/0171064 A1	09/02/2004	Dahlen et al.	
	11.	US 2004/0176914 A1	09/09/2004	Blankenberg et al.	
	12.	US 2004/0203083 A1	10/14/2004	Buechler et al.	
	13.	US 2004/0209307 A1	10/21/2004	Valkirs et al.	
	14.	US 2004/0219509 A1	11/04/2004	Valkirs et al.	
	15.	US 2005/0148024 A1	07/07/2005	Buechler	
	16.	US 2005/0164317 A1	07/28/2005	Buechler et al.	
	17.	US 2005/0181386 A1	08/18/2005	Diamond et al.	
	18.	US 2005/0244902 A1	11/03/2005	Goetze et al.	
	19.	US 2005/0255484 A1	11/17/2005	Valkirs et al.	
	20.	US 2006/0051825 A1	03/09/2006	Buechler et al.	
	21.	US 2006/0105419 A1	05/18/2006	Blankenberg et al.	
	22.	US 2007/0196880 A1	08/23/2007	Buechler et al.	
	23.	US 2007/0218498 A1	09/20/2007	Buechler et al.	
	24.	US 2007/0224643 A1	09/27/2007	Mcpherson et al.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/603,891	
			Filing Date	June 24, 2003	
			First Named Inventor	Kenneth F. Buechler	
			Art Unit	1641	
			Examiner Name	Unsu Jung	
Sheet	2	Of	10	Attorney Docket Number	36671-745.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	25.	US 2007/0269836 A1	11/22/2007	Mcpherson	
	26.	US 2008/0045444 A1	02/21/2008	Whittaker	
	27.	US 2008/0118924 A1	05/22/2008	Buechler	
	28.	US 4,900,662	02/13/1990	Shah et al.	
	29.	US 5,202,234	04/13/1993	Shah et al.	
	30.	US 5,290,678	03/01/1994	Jackowski	
	31.	US 5,382,515	01/17/1995	Shah et al.	
	32.	US 5,382,522	01/17/1995	Shah et al.	
	33.	US 5,580,722	12/03/1996	Foulkes et al.	
	34.	US 5,683,885	11/04/1997	Kieback	
	35.	US 5,747,274	05/05/1998	Jackowski	
	36.	US 5,786,163	07/28/1998	Hall	
	37.	US 6,174,686 B1	01/16/2001	Buechler et al.	
	38.	US 6,579,687 B1	06/17/2003	Buechler et al.	
	39.	US 6,627,404 B1	09/30/2003	Buechler et al.	
	40.	US 6,939,678 B1	09/06/2005	Buechler et al.	
	41.	US 6,991,907 B1	01/31/2006	Buechler et al.	
	42.	US 7,341,838 B2	03/11/2008	Buechler et al.	
	43.	US 7,358,055 B2	04/15/2008	Valkirs et al.	
	44.	US 7,361,473 B2	04/22/2008	Valkirs et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/603,891	
				Filing Date	June 24, 2003	
				First Named Inventor	Kenneth F. Buechler	
				Art Unit	1641	
				Examiner Name	Unsu Jung	
Sheet	3	Of	10	Attorney Docket Number		36671-745.502

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	45.	EP 1666881 A2	06/07/2006	Valkirs et al.		
	46.	GB 2248688 A	04/15/1992	Jackowski		
	47.	WO 2001/042793 A2	06/14/2001	Hochstrasser et al.		
	48.	WO 2001/042793 A3	12/06/2001	Hochstrasser et al.		
	49.	WO 2002/023191 A1	03/21/2002	Christopherson et al.		
	50.	WO 2004/058055 A2	07/15/2004	Anderberg et al.		
	51.	WO 2004/059293 A2	07/15/2004	Buechler et al.		
	52.	WO 2004/094460 A2	11/04/2004	Buechler et al.		
	53.	WO 2005/029088 A2	03/31/2005	Hochstrasser et al.		
	54.	WO 2005/029088 A3	09/15/2005	Hochstrasser et al.		
	55.	WO1993/024531	12/09/1993	Hall et al.		
	56.	International Search Report dated 4/30/2008 from PCT Application No. US 2007/69475	04/30/2008			
	57.	European Search Report dated 10/16/2007 for EP Application No. EP07107064.3	10/16/2007			

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	ADAMS et al., Diagnosis of Perioperative Myocardial Infarction with Measurement of Cardiac Troponin I N Engl J Med, 330:670-674 (1994)

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/603,891
				Filing Date	June 24, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
				Examiner Name	Unsu Jung
Sheet	4	Of	10	Attorney Docket Number	36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	59.	ADAMS, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. <i>Circulation</i> . 1993; 88: 101-106.
	60.	AL-AHMAD et al. Reduced Kidney Function and Anemia as Risk Factors for Mortality in Patients With Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> . 2001 Oct; 38(4).
	61.	BAIG, et al. The pathophysiology of advanced heart failure. <i>Am Heart J</i> . 1998 Jun;135(6 Pt 2 Su):S216-230.
	62.	BELLORINI et al. Interest of BNP and Troponin in the Management of Cardiologic Emergency. <i>J. of European Society of Cardiology</i> . 2001 Sept 1-5; 22: 518.
	63.	BETTENCOURT, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. <i>Cardiology</i> . 2000;93(1-2):19-25.
	64.	BIASUCCI, L. M. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. <i>Circulation</i> . 2004 Dec 21;110(25):e560-7.
	65.	BLENNOW, et al. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. <i>J Neural Transm Suppl</i> . 1998;53:223-35.
	66.	BLUM, et al. The role of inflammation in atherosclerosis. <i>Isr J Med Sci</i> . 1996 Nov;32(11):1059-65.
	67.	BOOMSMA, et al. Plasma A- and B-type Natriuretic Peptides: Physiology; Methodology and Clinical Use. <i>Cardiovascular Research</i> . 2001; 51:442-449.
	68.	BRUNNER-LA ROCCA, et al. Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? <i>Chest</i> . 1999 Oct;116(4):861-7.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/603,891	
				Filing Date	June 24, 2003	
				First Named Inventor	Kenneth F. Buechler	
				Art Unit	1641	
				Examiner Name	Unsu Jung	
Sheet	5	Of	10	Attorney Docket Number		36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	69.	CHEN et al. The Natriuretic Peptides in Heart Failure: Diagnostic and Therapeutic Potentials. Proceedings of the Assoc of American Physicians. 1999 Sept/Oct; 111(5):406-416.
	70.	CHO, et al. Natriuretic peptides and their therapeutic potential. Heart Dis. 1: 305-28, (1999).
	71.	CHRISTENSON, et al. Biochemical markers of the acute coronary syndromes. Clin Chem. 1998 Aug;44(8 Pt 2):1855-64.
	72.	CHU et al. A Review of Clinically Relevant Cardiac Biochemical Markers, Wisconsin Medical Journal. 2002; 101(3):40-48.
	73.	CLERICO, et al. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clinical Chemistry. 2004; 50(1):33-50.
	74.	DAGGUBATI, et al. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res. 1997 Nov;36(2):246-55.
	75.	DE LEMOS et al. Combining Natriuretic Peptides and Necrosis Markers in the Assessment of Acute Coronary Syndromes. Reviews in Cardiovascular Medicine. 2003; 4(4): S37-S46.
	76.	DUFFUS, et al. Glossary for chemists of terms used in toxicology. 1993; Pure & Appl. Chem. 65 (9) : 2003-2122.
	77.	ESPINER, et al. Natriuretic hormones. Endocrinol Metab Clin North Am. 1995 Sep;24(3):481-509.
	78.	FONAROW, et al. Combining Natriuretic Peptides and Necrosis Markers In Determining Prognosis in Heart Failure. Reviews in Cardiovascular Medicine. 2003; 4(4):S20-S28.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/603,891	
			Filing Date	June 24, 2003	
			First Named Inventor	Kenneth F. Buechler	
			Art Unit	1641	
			Examiner Name	Unsu Jung	
Sheet	6	Of	10	Attorney Docket Number	36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	79.	FU, et al. Proteomics and heart disease: identifying biomarkers of clinical utility. Expert Rev Proteomics. 2006 Apr;3(2):237-49.
	80.	HARRINGTON, J.R. The Role of MCP-1 in Atherosclerosis. Stem Cells. 2000;18: 65-66.
	81.	JANCIN B. Rapid test Helps Identify Cause of Dyspnea - Point-of-Care Brain Natriuretic Peptide Immunoassay, [on-line]. Retrieved from the Internet 2004 Oct 18; <uRL: <a href="http://www.findarticles.com/p/articles/mi_m0BJI/is_9_30/ai_63125276/0...">http://www.findarticles.com/p/articles/mi_m0BJI/is_9_30/ai_63125276/0...</a> : 2.
	82.	JEFFREY, S. BNP Diagnostic Test for CHF Receives FDA Approval. TheHeart.org. Available at: <a href="http://www.theheart.org">http://www.theheart.org</a> . Accessed on August 3, 2008.
	83.	JONES, et al. Elevated brain natriuretic peptide in septic patients without heart failure. Ann Emerg Med. 2003 Nov;42(5):714-5.
	84.	Journal of the American College of Cardiology, Myocardial infarction redefined – A Consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. 36:959-969, 2000.
	85.	KATRUKHA, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem. 1997 Aug;43(8 Pt 1):1379-85.
	86.	KUCHER, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003 Apr 1;107(12):1576-8.
	87.	KUCHER, et al. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003 May 27;107(20):2545-7.
	88.	LAINCHBURY, et al. Brain Natriuretic Peptide and N-Terminal Brain Natriuretic Peptide in the Diagnosis of Heart Failure in Patients With Acute Shortness of Breath. J. Am. Coll. Cardiol. 2003 Aug 20; 42(4):728-35.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/603,891	
				Filing Date	June 24, 2003	
				First Named Inventor	Kenneth F. Buechler	
				Art Unit	1641	
				Examiner Name	Unsu Jung	
Sheet	7	Of	10	Attorney Docket Number		36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	89.	LINDON, J. C. Biomarkers: Present concepts and future promise. Preclinica. 2003;1: 221.
	90.	MAEDER, et al. Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. Swiss Med Wkly. 2003 Sep 26;133(37-38):515-8.
	91.	MAISEL A. Cardiac Biomarkers Aid in Diagnosing Ischemia and Heart Failure. CVR&R, 2001 Apr; 22(4): 217-222.
	92.	MAISEL, A. Algorithms for using B-type natriuretic Peptide levels in the diagnosis and management of congestive heart failure. Crit Pathw Cardiol. 2002 Jun;1(2):67-73.
	93.	MAISEL, A. B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovasc Med. 2001;2 Suppl 2:S13-8.
	94.	MAISEL, A. Practical approaches to treating patients with acute decompensated heart failure. J Card Fail. 2001 Jun;7(2 Suppl 1):13-7.
	95.	MAISEL, et al. Measuring BNP levels in the diagnosis and treatment of CHF. Journal of Critical Illness. 2002; 17(11) (10 pages)
	96.	MAISEL, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul 18;347(3):161-7.
	97.	MCCULLOUGH et al. B-Type Natriuretic Peptide and Renal Function in the Diagnosis of Heart Failure: An Analysis From the Breathing Not Properly Multinational Study. American Journal of Kidney Diseases. 2003 Mar; 41(3):571-579.
	98.	MCGEOCH, et al: Plasma Brain Natriuretic Peptide After Long-Term Treatment for Heart Failure in General Practice, The European Journal of Heart Failure, 2002, pp. 479-483, Vol. 4, Elsevier Science B.V.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/603,891	
			Filing Date	June 24, 2003	
			First Named Inventor	Kenneth F. Buechler	
			Art Unit	1641	
			Examiner Name	Unsu Jung	
Sheet	8	Of	10	Attorney Docket Number	36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	99.	MCLEAN, et al. Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. <i>Anaesth Intensive Care</i> . 2003 Feb;31(1):21-7.
	100.	MCNAIRY, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. <i>Am Heart J</i> . 2002 Mar;143(3):406-11.
	101.	MEYER, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. <i>J Am Coll Cardiol</i> . 2000 Nov 1;36(5):1632-6.
	102.	NAGANUMA, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. <i>Am J Nephrol</i> . 2002 Sep-Dec;22(5-6):437-44.
	103.	PEACOCK, W. The B-type natriuretic peptide assay: a rapid test for heart failure. <i>Cleve Clin J Med</i> . 2002 Mar;69(3):243-51.
	104.	RICHARDS et al., B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction, <i>Circulation</i> , 2003 June 10; 107:2786-92.
	105.	RICHARDS et al., Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin; New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction, 1998 May 19; 97:1921-1929.
	106.	RISTORI, et al. Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. <i>J Neuroimmunol</i> . 1998 Aug 1;88(1-2):9-12.
	107.	SAFLEY, et al. The emerging role of brain natriuretic peptide in the management of acute and chronic heart failure in outpatients. <i>Heart Fail Monit</i> . 2003;4(1):13-20.
	108.	SAMAMA, M. Pulmonary embolism: controversies in laboratory studies. <i>Pathophysiol Haemost Thromb</i> . 2006;35(1-2):157-61.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/603,891	
				Filing Date	June 24, 2003	
				First Named Inventor	Kenneth F. Buechler	
				Art Unit	1641	
				Examiner Name	Unsu Jung	
Sheet	9	Of	10	Attorney Docket Number		36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	109.	SCHWAGERL, et al. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J. neurochem. 1995, vol. 64, no1, pp. 443-446.
	110.	SHAPIRO, et al. Use of Plasma Brain Natriuretic Peptide Concentration to Aid in the Diagnosis of Heart Failure. Mayo Clin Proc. 2003;78:481-486.
	111.	THE JOINT EUROPEAN SOCIETY OF CARDIOLOGY/AMERICAN COLLEGE OF CARDIOLOGY COMMITTEE, Consensus Document, Myocardial Infarction Redefined - A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction, Eur. Heart J., 2000 September; 21:18:1502-1513.
	112.	TSEKOURA, et al. Brain natriuretic peptide. HJC. 2003; 44:266-270.
	113.	TULEVSKI, I. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 2002 Jun 19;39(12):2080.
	114.	WATSON, et al. Clinical utility of biochemical analysis of cerebrospinal fluid. Clin Chem. 1995 Mar;41(3):343-60.
	115.	WELLS, et al., Excluding Pulmonary Embolism at the Bedside Without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and b-Dimer Ann. Intern. Med. 135:98-107 (2001)
	116.	WIECZOREK, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002 Nov;144(5):834-9.
	117.	WIJNBERGER, et al. Expression in the placenta of neuronal markers for perinatal brain damage. Pediatr Res. 2002 Apr;51(4):492-6.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/603,891	
				Filing Date	June 24, 2003	
				First Named Inventor	Kenneth F. Buechler	
				Art Unit	1641	
				Examiner Name	Unsu Jung	
Sheet	10	Of	10	Attorney Docket Number		36671-745.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	118.	WOOD, S. Breathing Not Properly Trial Indicates BNP Tests Should Be Incorporated Into ACC/AHA CHF Guidelines. TheHeart.org. Available at: <a href="http://www.theheart.org">http://www.theheart.org</a> . Accessed on August 03, 2008.
	119.	WRIGHT et al., Plasma Amino-terminal Pro-Brain Natriuretic Peptide and accuracy of Heart-Failure Diagnosis in Primary Care, J. Am. Coll. Cardiol., 2003 November 19; Elsevier Inc. 42:10:1793-1800.
	120.	YAMAMOTO, et al. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997 Nov;273(5 Pt 2):H2406-14.
	121.	ZOCCALI et al., Cardiac Natriuretic Peptides are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients, J. Am. Soc. Nephrol, 2001; 12:1508-1515.

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.